NCT03133923View on ClinicalTrials.gov

Phase II of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Infants

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1,080

Participants

Timeline

Start Date

May 20, 2017

Primary Completion Date

November 10, 2017

Study Completion Date

July 1, 2024

Conditions
Epidemic Parotitis,Mumps
Interventions
BIOLOGICAL

≥3.0 lgCCID50/mlbut <3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)

≥3.0 lgCCID50/ml but \<3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day

BIOLOGICAL

≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)

≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day

BIOLOGICAL

Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)

Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day

Trial Locations (1)

430079

Hubei Provincial Center for Disease Control and Prevention, Wuhan

All Listed Sponsors
collaborator

Hubei Provincial Center for Disease Control and Prevention

OTHER

lead

Institute of Medical Biology, Chinese Academy of Medical Sciences

OTHER